Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263299 | 0.89 | CNR1 (0.42) | PPARGEPHX2ITGB1ITGA4ITGB7 | |
| SCHEMBL2266394 | 0.87 | MTNR1A (0.43) | PPARGEPHX2ITGB1ITGA4ITGB7 | |
| SCHEMBL2266775 | 0.85 | ALDH1A1 (0.44) | PPARGEPHX2CNR1ELANE | |
| SCHEMBL2262250 | 0.85 | EPHX2 (0.48) | PPARGEPHX2 | |
| SCHEMBL2263963 | 0.85 | L3MBTL1 (0.43) | PPARGEPHX2ITGB1ITGA4ITGB7 | |
| SCHEMBL2263570 | 0.84 | TP53 (0.43) | PPARGEPHX2ITGB1ITGA4ITGB7 | |
| SCHEMBL14944146 | 0.83 | NPC1 (0.39) | PPARGEPHX2ITGB1ITGA4ITGB7 | |
| SCHEMBL12390328 | 0.82 | CNR1 (0.44) | PPARGEPHX2ITGB1ITGA4ITGB7 | |
| SCHEMBL12390431 | 0.78 | NPC1 (0.42) | PPARG | |
| SCHEMBL12366594 | 0.78 | CNR1 (0.45) | PPARGITGB1ITGA4ITGB7CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | PPARG 25/4885EPHX2 1951/4885ITGB1 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.